Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Holly Elizabeth Rawizza, M.D.

Other Positions

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01HD100726 (RAWIZZA, HOLLY ELIZABETH) Apr 7, 2022 - Jan 31, 2027
    Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention
    Role: Principal Investigator
  2. R21AI162201 (RAWIZZA, HOLLY ELIZABETH) Sep 7, 2021 - Aug 31, 2023
    Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir use
    Role: Principal Investigator
  3. R21AI150347 (RAWIZZA, HOLLY ELIZABETH) Mar 9, 2020 - Feb 28, 2022
    Rifabutin pharmacokinetics and safety among HIV/TB coinfected infants receiving lopinavir
    Role: Principal Investigator
  4. K23AI125122 (RAWIZZA, HOLLY ELIZABETH) Mar 1, 2016 - Jan 31, 2022
    Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Chaplin B, Agbaji O, Reyes Nieva H, Olatunde B, Chang C, Mitruka K, Sule H, Dajel T, Zee A, Ahmed ML, Ahmed I, Okonkwo P, Rawizza H, Kanki P. Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria. Clin Infect Dis. 2023 02 08; 76(3):e671-e680. PMID: 35872644.
    Citations:    Fields:    
  2. Rawizza HE, Oladokun R, Ejeliogu E, Oguche S, Ogunbosi BO, Agbaji O, Odaibo G, Imade G, Olaleye D, Wiesner L, Darin KM, Okonkwo P, Kanki PJ, Scarsi KK, McIlleron HM. Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART. J Antimicrob Chemother. 2021 02 11; 76(3):710-717. PMID: 33294914.
    Citations: 1     Fields:    Translation:Humans
  3. Nazziwa J, Faria NR, Chaplin B, Rawizza H, Kanki P, Dakum P, Abimiku A, Charurat M, Ndembi N, Esbjörnsson J. Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread. Sci Rep. 2020 02 26; 10(1):3468. PMID: 32103028.
    Citations: 6     Fields:    Translation:HumansCells
  4. Rawizza HE, Darin KM, Oladokun R, Brown B, Ogunbosi B, David N, Akanmu S, Olaitan O, Chang C, Scarsi KK, Okonkwo P, Kanki PJ. Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART. J Antimicrob Chemother. 2019 09 01; 74(9):2707-2715. PMID: 31139825; PMCID: PMC6736350.
    Citations: 4     Fields:    Translation:Humans
  5. Rabie H, Rawizza H, Zuidewind P, Winckler J, Zar H, Van Rie A, Wiesner L, McIlleron H. Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. J Antimicrob Chemother. 2019 08 01; 74(8):2347-2351. PMID: 31081020.
    Citations: 2     Fields:    Translation:Humans
    Citations: 3     
  7. Chaplin B, Imade G, Onwuamah C, Odaibo G, Audu R, Okpokwu J, Olaleye D, Meloni S, Rawizza H, Muazu M, Musa AZ, Samuel J, Agbaji O, Ezechi O, Idigbe E, Kanki PJ. Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2018 02; 34(2):228-233. PMID: 29084434; PMCID: PMC6836671.
    Citations: 1     Fields:    Translation:HumansCells
  8. Meloni ST, Onwuamah CK, Agbaji O, Chaplin B, Olaleye DO, Audu R, Samuels J, Ezechi O, Imade G, Musa AZ, Odaibo G, Okpokwu J, Rawizza H, Mu'azu MA, Dalhatu I, Ahmed M, Okonkwo P, Raizes E, Ujah IAO, Yang C, Idigbe EO, Kanki PJ. Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options. Open Forum Infect Dis. 2017; 4(4):ofx233. PMID: 29255731; PMCID: PMC5726477.
    Citations: 2     
  9. Knelson EH, Vaidya A, Rawizza HE, Vaduganathan M, O'Gara PT. On the Cusp. N Engl J Med. 2017 05 25; 376(21):e45. PMID: 28538122.
    Citations:    Fields:    Translation:HumansCells
  10. Rawizza H. Triple-drug antiretroviral therapy results in lower HIV maternal-fetal transmission rates but increased adverse effects compared with zidovudine alone. J Pediatr. 2017 03; 182:401-404. PMID: 28237453.
    Citations:    Fields:    Translation:HumansPHPublic Health
  11. Dugdale C, Brown S, Davila C, Wolkow N, Fishbein G, Sun J, Barkoudah E, Rawizza H. Out of Sight: Culture-Negative Endocarditis and Endophthalmitis. Am J Med. 2017 02; 130(2):e51-e53. PMID: 27637598; PMCID: PMC5263175.
    Citations: 1     Fields:    Translation:Humans
  12. Scarsi KK, Eisen G, Darin KM, Meloni ST, Rawizza HE, Tchetgen Tchetgen EJ, Agbaji OO, Onwujekwe DI, Gashau W, Nkado R, Okonkwo P, Murphy RL, Kanki PJ. Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. Clin Infect Dis. 2016 Feb 15; 62(4):512-8. PMID: 26561532; PMCID: PMC4725384.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  13. Chang CA, Meloni ST, Eisen G, Chaplin B, Akande P, Okonkwo P, Rawizza HE, Tchetgen Tchetgen E, Kanki PJ. Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria. Open Forum Infect Dis. 2015 Dec; 2(4):ofv154. PMID: 26613097; PMCID: PMC4654399.
    Citations: 13     
  14. Meloni ST, Chaplin B, Chang C, Rawizza H, Okonkwo P, Kanki PJ. Patterns of Adherence and Loss to Follow-Up in Pediatric Patients on ART in Nigeria. Curr HIV Res. 2015; 13(3):210-8. PMID: 25986372.
    Citations: 4     Fields:    Translation:Humans
  15. Rawizza HE, Chang CA, Chaplin B, Ahmed IA, Meloni ST, Oyebode T, Banigbe B, Sagay AS, Adewole IF, Okonkwo P, Kanki PJ. Loss to Follow-Up within the Prevention of Mother-to-Child Transmission Care Cascade in a Large ART Program in Nigeria. Curr HIV Res. 2015; 13(3):201-9. PMID: 25986371; PMCID: PMC5495655.
    Citations: 22     Fields:    Translation:HumansPHPublic Health
  16. Meloni ST, Chang C, Chaplin B, Rawizza H, Jolayemi O, Banigbe B, Okonkwo P, Kanki P. Time-Dependent Predictors of Loss to Follow-Up in a Large HIV Treatment Cohort in Nigeria. Open Forum Infect Dis. 2014 Sep; 1(2):ofu055. PMID: 25734125; PMCID: PMC4281819.
    Citations: 33     
  17. Rawizza HE, Chaplin B, Meloni ST, Darin KM, Olaitan O, Scarsi KK, Onwuamah CK, Audu RA, Chebu PR, Imade GE, Okonkwo P, Kanki PJ. Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. PLoS One. 2013; 8(9):e73582. PMID: 24069209.
    Citations: 27     Fields:    Translation:HumansCells
  18. Dinic L, Idigbe OE, Meloni S, Rawizza H, Akande P, Eisen G, Onwujekwe D, Agbaji O, Ani A, Kanki PJ. Sputum smear concentration may misidentify acid-fast bacilli as Mycobacterium tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr. 2013 Jun 01; 63(2):168-77. PMID: 23392466.
    Citations: 2     Fields:    Translation:HumansCells
  19. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé JL, Dieng-Sarr A, Agbaji O, Onwujekwe DI, Gashau W, Nkado R, Ekong E, Okonkwo P, Murphy RL, Kanki PJ. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011 Dec; 53(12):1283-90. PMID: 22080121.
    Citations: 82     Fields:    Translation:Humans
  20. Rawizza HE, Sax PE. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases. AIDS Read. 2008 Sep; 18(9):466-72, 478-9. PMID: 18828231.
    Citations:    Fields:    Translation:Humans
  21. Rawizza, Holly. Black Women Underrepresented in HIV Research. AIDS Clinical Care. 2007; 19(5):47.
  22. Holly Rawizza and Paul E. Sax. Management of HIV Infection. Internal Medicine Board Review Manual. 2007; 11(4):2-17.
  23. Rawizza, Holly. Undetectable HCV Viral Load Without Treatment--Monitoring Required. AIDS Clinical Care. 2007; 19(3).
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu. SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Rawizza's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (96)
Co-Authors (14)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.